Trius Therapeutics

Trius Therapeutics (NASDAQ: TSRX) was a biopharma company based in San Diego, CA that focused on the development of antibiotics.[1]

Business profile

The lead compound from Trius, tedizolid phosphate (formerly torezolid phosphate, TR-701), successfully completed its first Phase 3 clinical trial (ESTABLISH 1) in acute skin and skin structure infections (ABSSSI).[2] It is a once daily, IV and oral, oxazolidinone being developed for the treatment of serious grampositive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).[3] The Phase 3 trials are being conducted under a Special Protocol Agreement with the US Food and Drug Administration and are using the draft FDA guidance of cessations of lesion spread at 48–72 hours as the primary endpoint.[4] In the ESTABLISH 1 Study, 200 mg of Tedizolid given for a short course of therapy (six days) was shown to be safe, well tolerated and was as effective as the traditional length of therapy with linezolid (600 mg for ten days).[5] Additionally, Tedizolid was shown to have fewer treatment-related side effects than linezolid and significantly fewer GI side effects.[6]

Trius was planning the second Phase 2 trial and expects to report results around the end of Q1 2013 and planned to submit an NDA to the FDA for the drug in the second half of 2013.[7]

Tedizolid was approved by the US Food and Drug Administration on June 20, 2014.

The firm was acquired by Cubist Pharmaceuticals at the end of July 2013 in a deal worth $1.6 billion. This fee also included the purchase of Optimer Pharmaceuticals.[8]

Funding

In February 2007 Trius was formed (formerly Rx3) in conjunction with a Series A financing.[9] Trius completed an initial public offering in August 2010, raising $50 million.[10] Its stock was added to the NASDAQ Biotechnology Index in 2012.[11]

Partnerships and Government Contracts

In 2008 the company received a $28 million contract from the National Institute of Allergy and Infectious Diseases a component of the National Institutes of Health, to develop antibiotics against gram-negative infections. The work included a collaboration with the Lawrence Livermore National Laboratory to help identify antibiotics against gram-negative infections and bioterrorism.[12] Trius was awarded a contract by Lawrence Livermore National Laboratory in 2011 for $3 million.[13] In 2011 Bayer acquired the exclusive rights to Trius' antibiotic tedizolid in certain areas in Asia, Africa, the Middle East, and Latin America.[14] The deal was reported as being worth $94 million.[15]

Employees

Trius was founded by the last Chief Financial Officer John Schmid and Chief Scientific Officer John Finn.[16] Other executives included Chief Executive Officer Jeffrey Stein, Chief Medical Officer Philippe Prokocimer, Chief Commercial Officer Craig Thompson,[17] and Chief Development Officer Ken Bartizal.[18] The Chairman of the Board is David Kabakoff.[19] The company today has 83 full-time employees.[20]

References

  1. ↑ "Trius Therapeutics - About". Triusrx.com. Retrieved 26 July 2012.
  2. ↑ http://seekingalpha.com/article/821901-an-investment-update-on-trius-therapeutics-tedizolid. Missing or empty |title= (help)
  3. ↑ http://www.nasdaq.com/article/trius-therapeutics-announces-data-presentations-on-tedizolid---quick-facts-20120911-01047. Missing or empty |title= (help)
  4. ↑ http://seekingalpha.com/article/821901-an-investment-update-on-trius-therapeutics-tedizolid. Missing or empty |title= (help)
  5. ↑ http://www.fiercebiotech.com/story/trius-shares-surge-antibiotic-matches-zyvox-pivotal-phiii/2011-12-19. Missing or empty |title= (help)
  6. ↑ http://smithonstocks.com/component/content/article/3/261-trius-therapeuticsarsquo-tedizolid-has-blockbuster-potential-for-mrsa-infections-tsrx-505. Missing or empty |title= (help)
  7. ↑ Darcé, Keith (31 October 2011). "Trius grows as lead antibiotic moves forward". San Diego Union-Tribune. Retrieved 5 September 2012.
  8. ↑ Vrinda Manocha and Zeba Siddiqui (30 July 2013). "Cubist to pay up to $1.6 billion for two antibiotics makers". Reuters.
  9. ↑ http://www.fiercebiotech.com/special-reports/emerging-drug-developer-trius-therapeutics. Missing or empty |title= (help)
  10. ↑ Scholer, Kristen; Spears, Lee (3 August 2010). "Trius Therapeutics Initial Offer Raises $50 Million". Bloomberg.
  11. ↑ "Semi-Annual Changes to the NASDAQ Biotechnology Index". MarketWatch. Retrieved 27 July 2012.
  12. ↑ Timmermeyer, Luke (22 October 2008). "Trius Therapeutics Wins $28M Contract From NIH For Bioterror Antibiotics". Xconomy. Retrieved 5 September 2012.
  13. ↑ https://web.archive.org/web/20120420044649/http://www.reuters.com/finance/stocks/TSRX.O/key-developments/article/2291312. Archived from the original on April 20, 2012. Missing or empty |title= (help)
  14. ↑ Conover, Damien (3 September 2012). "Premium Articles 5 Big Pharma Opportunities in Emerging Markets". Morning Start. Retrieved 5 September 2012.
  15. ↑ Darcé, Keith (27 July 2012). "Trius signs $94 million licensing deal for lead antibiotic". San Diego Union-Tribune. Retrieved 5 September 2012.
  16. ↑ "Trius Therapeutics Inc". Bloomberg News. Retrieved 5 September 2012.
  17. ↑ http://www.sec.gov/Archives/edgar/data/1356857/000119312512115086/d270282d10k.htm. Missing or empty |title= (help)
  18. ↑ http://www.sec.gov/Archives/edgar/data/1356857/000119312512115086/d270282d10k.htm. Missing or empty |title= (help)
  19. ↑ "Trius Therapeutics, Inc. Executives". Hoover's. Retrieved 5 September 2012.
  20. ↑ "Company Overview of Trius Therapeutics, Inc.". Businessweek. Retrieved 5 September 2012.

External links

This article is issued from Wikipedia - version of the 10/10/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.